Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > CEO buying as he said......
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(351)
•••
Comment by woundedkneeon Sep 25, 2020 6:10am
185 Views
Post# 31618854

RE:RE:RE:RE:RE:CEO buying as he said......

RE:RE:RE:RE:RE:CEO buying as he said......I held on after ATE started its downtrend from the eighties after the phase11 results and sold all of my holdings in the mid sixties. I bought back in the mid forties and I agree, that it is a hold on this stock and not a sell, that is if you already own a subsantial amount of shares. It will take a while for all of this to iron out. There are things we know and things we don't know about the future of ATE. My comments regarding "don't buy" were strictly aimed at new buyers, also to those wishing to average down. We are now in a downtrend and at sometime this will end. But I would sooner buy when the stock is rising, even though you may miss the bottom by a cent or two. If I had followed my own advice, I would be a shareholder in waiting and several thousand dollars richer. My comments are JMO. gl
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities